Cardiovascular Disease in HIV Patients: A Comprehensive Review

The landscape of HIV care has dramatically shifted with advancements in antiretroviral therapy, leading to increased life expectancy for individuals living with HIV. However, this prolonged survival has unveiled a novel set of health challenges, notably a heightened risk of cardiovascular disease (CVD). This article provides a comprehensive overview of the relationship between HIV and CVD, exploring the underlying mechanisms, clinical manifestations, diagnostic approaches and treatment strategies.

The Rising Prevalence of CVD in HIV

Historically, CVD was less common in people with HIV due to the relatively short survival times before the advent of effective antiretroviral therapies. However, as individuals with HIV now live longer, the prevalence of cardiac involvement has significantly increased, ranging from 28% to 73% ¹. This rise underscores the need for increased awareness and proactive cardiovascular risk management in this population.

Pathogenesis of HIV-Associated Cardiovascular Disease

The development of CVD in individuals with HIV is multifactorial, involving both direct and indirect effects of the virus and its treatment. Advances in cardiac imaging and immunology have deepened our understanding of these complex processes ². Key contributing factors include:

• HIV-induced inflammation: Chronic immune activation, a hallmark of HIV infection, promotes systemic inflammation, contributing to atherosclerosis and endothelial dysfunction.
• Antiretroviral therapy (ART): While life-saving, some ART regimens, particularly older protease inhibitors, have been associated with dyslipidemia (abnormal lipid levels) and insulin resistance, increasing CVD risk.
• Viral proteins: HIV proteins like gp120 can directly damage the heart muscle and contribute to myocardial dysfunction.
• Co-morbidities: Individuals with HIV often have a higher prevalence of traditional CVD risk factors, such as hypertension, diabetes, and smoking.

Clinical Manifestations of CVD in HIV

HIV-associated CVD can manifest in various forms, including:

• Coronary artery disease (CAD): The most common form, leading to angina, myocardial infarction (heart attack), and heart failure.
• Cardiomyopathy: Weakening of the heart muscle, potentially leading to heart failure. Research highlights the significant impact of HIV on cardiomyopathy ⁴.
• Heart failure: The heart’s inability to pump enough blood to meet the body’s needs.
• Arrhythmias: Irregular heartbeats.
• Pulmonary hypertension: High blood pressure in the arteries of the lungs.
• Pericardial disease: Inflammation of the sac surrounding the heart.

Diagnosis and Management

Early detection and management of CVD in HIV-positive individuals are crucial. The changing paradigm regarding the long-term impact of HIV on cardiovascular health has increased attention to this area ³. Diagnostic approaches include:

• Traditional cardiovascular assessments: Electrocardiogram (ECG), echocardiogram, stress testing.
• Advanced imaging: Cardiac MRI, CT angiography to assess coronary artery disease and myocardial function.
• Biomarkers: Measuring levels of troponin, BNP (brain natriuretic peptide), and inflammatory markers.

Management strategies focus on:

• Optimizing ART: Selecting ART regimens with favorable lipid profiles.
• Managing traditional risk factors: Controlling blood pressure, cholesterol, and blood sugar.
• Lifestyle modifications: Encouraging a healthy diet, regular exercise, and smoking cessation.
• Pharmacological interventions: Utilizing medications to treat heart failure, arrhythmias, and other cardiovascular conditions.

Future Directions

Ongoing research is focused on further elucidating the mechanisms underlying HIV-associated CVD and developing targeted therapies. A deeper understanding of the interplay between HIV, inflammation, and cardiovascular risk will be essential for improving the long-term health and well-being of individuals living with HIV.